Table 1.
Baseline Features of Older Women and Men With Out-of-Hospital MI
| Nonadjusted Patients | Weighted Patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Women | Men | Women | Men | |||||
| Variable | n = 20 131 | n = 20 523 | p Value | SMD | n = 20 239 | n = 20 451 | p Value | SMD |
| Age, y (SD) | 81.6 (6.3) | 78.7 (5.9) | <.0001 | 0.484 | 80.1 (6.4) | 80.1 (6.3) | .638 | 0.005 |
| Comorbidities | ||||||||
| Alcohol abuse | 0.5% | 1.9% | <.0001 | 0.127 | 1.2% | 1.2% | .951 | 0.001 |
| Anemia | 5.9% | 4.7% | <.0001 | 0.053 | 5.3% | 5.4% | .653 | 0.004 |
| Atrial fibrillation | 25.3% | 23.2% | <.0001 | 0.049 | 24.1% | 24.0% | .810 | 0.002 |
| Cerebrovascular disease | 15.6% | 16.5% | .019 | 0.023 | 16.0% | 16.1% | .859 | 0.002 |
| Chronic pulmonary disease | 14.1% | 16.9% | <.0001 | 0.079 | 15.9% | 15.7% | .567 | 0.006 |
| Coagulopathy | 0.4% | 0.4% | .411 | 0.008 | 0.4% | 0.4% | .960 | 0.0005 |
| Dementia | 12.2% | 9.0% | <.0001 | 0.104 | 10.6% | 10.7% | .609 | 0.005 |
| Depression | 16.0% | 9.1% | <.0001 | 0.192 | 10.3% | 10.5% | .385 | 0.009 |
| Diabetes | 28.3% | 27.3% | .015 | 0.024 | 27.7% | 27.7% | .979 | 0.0003 |
| Insulin dependent | 8.7% | 8.0% | .012 | 0.025 | 8.3% | 8.3% | .941 | 0.001 |
| Non-insulin dependent | 19.6% | 19.2% | .321 | 0.001 | 19.4% | 19.4% | .983 | 0.0002 |
| Heart failure | 40.5% | 31.5% | <.0001 | 0.187 | 35.7% | 35.8% | .924 | 0.001 |
| Hypertension | 64.5% | 52.5% | <.0001 | 0.246 | 58.2% | 58.1% | .821 | 0.002 |
| Hypothyroidism | 9.5% | 2.5% | <.0001 | 0.300 | 6.0% | 5.9% | .907 | 0.001 |
| Liver disease | 0.7% | 0.7% | .761 | 0.003 | 0.8% | 0.8% | .631 | 0.005 |
| Malignancy | 12.7% | 20.3% | <.0001 | 0.206 | 17.1% | 16.8% | .419 | 0.008 |
| Metastatic tumor | 0.3% | 0.4% | .451 | 0.007 | 0.3% | 0.3% | .942 | 0.001 |
| Paralysis | 0.4% | 0.4% | .797 | 0.003 | 0.4% | 0.4% | .697 | 0.004 |
| Peripheral vascular disease | 8.9% | 11.8% | <.0001 | 0.094 | 10.3% | 10.3% | .822 | 0.002 |
| Prior CABG | 2.5% | 5.5% | <.0001 | 0.152 | 4.0% | 4.0% | .962 | 0.0004 |
| Prior MI | 20.9% | 24.6% | <.0001 | 0.086 | 22.9% | 22.8% | .878 | 0.002 |
| Psychotic disorder | 3.9% | 2.4% | <.0001 | 0.090 | 3.1% | 3.2% | .539 | 0.006 |
| Rheumatic disease | 9.6% | 5.8% | <.0001 | 0.144 | 7.6% | 7.6% | .943 | 0.001 |
| Renal failure | 4.9% | 6.5% | <.0001 | 0.069 | 5.7% | 5.7% | .999 | <0.0001 |
| Valvular disease | 9.4% | 7.5% | <.0001 | 0.068 | 8.4% | 8.5% | .881 | 0.001 |
| Revascularization | 29.2% | 42.2% | <.0001 | 0.274 | 36.0% | 36.1% | .686 | 0.004 |
| PCI | 25.8% | 35.0% | <.0001 | 0.202 | 30.8% | 30.8% | .941 | 0.001 |
| CABG | 3.7% | 7.6% | <.0001 | 0.173 | 5.8% | 5.7% | .826 | 0.002 |
| ST elevation MI | 28.9% | 31.2% | <.0001 | 0.048 | 30.0% | 29.9% | .853 | 0.002 |
| Anteriora | 55.6% | 53.3% | .013 | 0.045 | 54.0% | 54.4% | .709 | 0.007 |
| Medication | ||||||||
| ADP inhibitor | 3.5% | 4.1% | .004 | 0.029 | 3.8% | 3.8% | .974 | 0.0003 |
| Antiarrhythmic | 0.4% | 0.6% | .003 | 0.030 | 0.5% | 0.5% | .740 | 0.003 |
| Anticoagulant | 9.1% | 10.7% | <.0001 | 0.055 | 9.8% | 9.9% | .811 | 0.002 |
| ACEi or ARB | 40.2% | 34.5% | <.0001 | 0.118 | 37.2% | 37.1% | .852 | 0.002 |
| Aldosterone antagonist | 2.9% | 1.6% | <.0001 | 0.075 | 2.1% | 2.2% | .740 | 0.003 |
| β-Blocker | 49.4% | 44.9% | <.0001 | 0.091 | 46.9% | 50.0% | .918 | 0.001 |
| Statin | 28.5% | 30.3% | <.0001 | 0.040 | 29.3% | 29.3% | .906 | 0.001 |
| Treating hospital (n = 20) | <.0001 | 0.059 | .195 | 0.002 | ||||
Notes: ACEi = angiotensin-converting-enzyme inhibitor; ADP = adenosine diphosphate; ARB = angiotensin receptor blocker; CABG = coronary artery bypass grafting surgery; MI = myocardial infarction; PCI = percutaneous coronary intervention; SMD = standardized mean difference.
aOf ST elevation MI patients. Features of all patients and inverse probability weight balanced cohort.